Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) issued its quarterly earnings data on Monday. The company reported ($2.44) earnings per share for the quarter, topping the consensus estimate of ($2.64) by $0.20, FiscalAI reports. The business had revenue of $13.54 million during the quarter, compared to the consensus estimate of $7.72 million. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.10%.

Here are the key takeaways from Tonix Pharmaceuticals’ conference call:

• TONMYA sales accelerated: Second-quarter net sales reached approximately $11 million, up 197% quarter over quarter, while prescriptions, new patient starts, and refills all increased. Management attributed the momentum to positive prescriber feedback, tolerability, and strong refill activity.
• Market access and commercial expansion are progressing: TONMYA coverage currently reaches about 136 million U.S. lives, with coverage expected to rise to approximately 145 million on January 1, 2027. Tonix is adding 50 sales representatives, bringing the field force to roughly 150 by September, to support broader geographic and prescriber coverage.
• Gross-to-net remains variable: Favorable retail and specialty distribution mix and lower copay assistance costs supported second-quarter results, but management expects continued quarterly fluctuations as new payer agreements generate downstream effects. Wholesaler inventory days remained consistent, with no reported incremental inventory buildup.
• Pipeline programs advanced: Tonix randomized the first patient in the phase II HORIZON study of TNX-102 SL for major depressive disorder and expects to begin enrollment of an adaptive phase II study of TNX-4800 for Lyme disease prevention in the first quarter of 2027. Management believes the Lyme study could potentially provide pivotal efficacy evidence if enough infections occur in the placebo group.
• Operating expenses and funding needs increased: Second-quarter R&D expense rose to approximately $19.4 million and SG&A to $36 million, largely due to clinical development and TONMYA commercial investments. Cash and equivalents declined to $176.2 million at quarter-end, with current resources and subsequent equity proceeds expected to fund operations into early second quarter 2027.

Tonix Pharmaceuticals Stock Down 2.0%

NASDAQ TNXP opened at $12.34 on Wednesday. Tonix Pharmaceuticals has a fifty-two week low of $9.40 and a fifty-two week high of $69.97. The business has a fifty day moving average of $11.63 and a 200-day moving average of $13.39. The stock has a market cap of $196.70 million, a price-to-earnings ratio of -0.95 and a beta of 1.69.

Wall Street Analysts Forecast Growth

TNXP has been the topic of a number of research analyst reports. Raymond James Financial reiterated a “strong-buy” rating and set a $27.00 target price on shares of Tonix Pharmaceuticals in a research report on Monday. TD Cowen upgraded Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. Weiss Ratings lowered Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.50.

Insider Activity

In other news, CEO Seth Lederman bought 5,000 shares of Tonix Pharmaceuticals stock in a transaction on Tuesday, June 9th. The shares were bought at an average cost of $11.79 per share, for a total transaction of $58,950.00. Following the acquisition, the chief executive officer owned 9,005 shares in the company, valued at approximately $106,168.95. This trade represents a 124.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard Newcomb Stillwell purchased 5,000 shares of the stock in a transaction dated Monday, June 8th. The shares were purchased at an average price of $11.65 per share, with a total value of $58,250.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $58,250. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 11,415 shares of company stock valued at $132,128 in the last three months. 2.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Tonix Pharmaceuticals by 238.1% during the 3rd quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock valued at $13,456,000 after buying an additional 392,225 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $2,895,000. Geode Capital Management LLC increased its stake in Tonix Pharmaceuticals by 182.4% during the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after acquiring an additional 113,175 shares during the last quarter. Nuveen LLC increased its position in Tonix Pharmaceuticals by 507.7% during the 4th quarter. Nuveen LLC now owns 93,402 shares of the company’s stock worth $1,459,000 after purchasing an additional 78,033 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new position in Tonix Pharmaceuticals in the third quarter valued at approximately $1,521,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.